Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%

What happened

Artiva Biotherapeutics said it would halt development of its experimental cell therapy AlloNK after two patient deaths in a mid-stage trial, cut its workforce by about 94%, and evaluate strategic alternatives.

Confirmed

Global impact / market context

Stopping the trial removes the company's main potential product, which means future revenue depends on finding a partner or buyer. The 94% workforce cut sharply lowers costs but also signals the company is winding down most operations.

Analyst inference

The 30% premarket share drop shows investors expect little value from AlloNK after the safety deaths. With about $319.1 million in cash as of September 30, Artiva may fund a sale or return cash rather than continue research.

Analyst inference

What to watch

1. Artiva said it is evaluating strategic alternatives, which means options such as a sale, merger, or other deal, and any announcement would show what remains for shareholders. Confirmed
2. Watch whether the company discloses the timing and cost of the 94% workforce reduction, since those details would show how much cash is preserved. Proposed
3. Track whether partners or buyers show interest in Artiva's remaining cell therapy technology, because a deal could change the value left for investors. Analyst inference

Evidence

• Original source link unavailable